yeah tell me about it. I rode that all the way down and almost cut the chord this morning but decided, no, I've already lost 17% of value, so I'll just keep it, and then bam, express elevator back up. Not to the top floor though. Yesterday was my second worst day in the market ever. (I'm heavily invested in immunology, CAR-T, gene therapy), so yesterday I lost 7.8% of my entire portfolio. Today I made two thirds of that loss back. What a WILD RIDE!!!!!
I don't know about that but I do know what's interesting about India and Sovaldi. I gather everyone is following the situation there where their patent office will not grant a sofosbuvir (sovaldi) patent because it isn't "inventive" enough from other similar molecules. Gilead is appealing, but we'll see if they apply that stupid logic to another uridine based NS5B, aka 3422. Here's what else is interesting: India is 75% Genotype 3 (50% gt3a, 25% gt3b), where 3422 shines.
This is why Yahoo boards suck. They simply cannot figure out how to present messages. One to another. It's so simple. Yahoo, call me and I will help.
Regarding the article I referred to, I welcome the thumbs down on it because, frankly, the author was not knowledgeable about zerenex/auryxia, and his argument points sucked.
Biobuddy, you still at Genzyme? So a short on this board is saying Greg was let go at Genzyme due to lower than projected sales of one of the key drugs . Is that true? Secondly, and unrelated to the first question, is it my imagination or does Genzyme and the FDA have a love affair going on? The FDA treats Genzyme with kid gloves on all of its trials, NDA's, and just about any interaction- at least that's my perception!? What did you do there?
wow, we have a flood of shorts on this thread all of a sudden and I have to defend my long position with suspicious fellow longs like Jeremy! What a day!
oh and one more point that is important: the market may not value this company for awhile, but that's not necessarily true of an acquirer. They know that peak sales can hit 1.5-2 billion (I know you think it's a lot higher. Maybe). As far as CKD results - they already have them - from Japan, so the drug has been largely de-risked for that indication.
"beating a hasty retreat from your baseless premise (Keryx's supposed inability to launch alone)" Where and in what post exactly did I say they were incapable of launching alone? Don't put words in my mouth Jeremy when so far you haven't comprehended the meaning of my posts at all. You probably discovered KERX six months ago and I discovered it six years ago so it's really inappropriate to try to lecture me about the merits or situation of this company. I'm done with you.
BTW, "expedite" means to "make it go faster". Do you not think a Sanofi, Roche, Amgen, or Fresenius would ramp this up faster than KERYX can do on their own, with their global presence? Of course it would! Do I think that KERYX can handle the roll out by themselves? Of course I do! Will it be slower? Of course it will!
OMG Jeremy, really? Can you only handle one idea at a time? The idea of a) selling the company and b) that the new CEO is very capable of rolling out the product, are not MUTUALLY EXCLUSIVE IDEAS! As I very clearly stated, I would rather have this company bought out for 3-4X its current price than wait 3 years for the PPS to get there. Can you honestly tell me that you wouldn't want that as well? And in my reply to that SA wirter, I said the same thing about the rollout - that KERX was capable of handling it with a small sales staff given the vertical nature of the ESRD and CKD market. But I still think it's best to find a good buyer at the right price now!
Jesus it would take two or three long posts to post my reply, and part of my reply was referencing things in the article, which if I posted that as well would be 7 or 8 posts.
Frankie, again, the main point of that post was to point out my reply, which if read by people who are relatively new to KERX might learn something from it. It systematically addresses every argument that the SA article writer (and others) have made about KERX. The NCE issue is still hanging and is an issue the shorts still bring up, but as many have pointed out - the success of Auryxia doesn't hang on whether it is a new chemical entity - they have plenty of IP without it. As a long holding a stock that has 27% of its outstanding shares sold short, you bet I vet every possible short argument to see if it holds water - and every other smart long should do the same for themselves if they haven't already. That's why I pointed out that article AND my response (along with several other commenters on that thread after the article), because in my view that whole exchange is one of the best ways to get a thorough education on this company and drug.